B. Bach

发表

Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors.

J. Baselga, P. LoRusso, J. Tabernero, 2010 .

First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.

J. Blay, G. Demetri, R. Maki, 2012, European journal of cancer.

Surgical Downstaging in an Open-Label Phase II Trial of Denosumab in Patients with Giant Cell Tumor of Bone

J. Wunder, P. Rutkowski, S. Ferrari, 2015, Annals of Surgical Oncology.

Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer

P. Gibbs, Tae Won Kim, M. Peeters, 2018, Clinical Cancer Research.

Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial

H. Wildiers, B. Arun, M. Friedlander, 2021, Therapeutic advances in medical oncology.

Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (-) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Analysis of the global phase III SPECTRUM trial.

S. Faivre, E. Winquist, S. Rottey, 2012 .

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer

A. Bardelli, E. Van Cutsem, J. Tabernero, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of emergent circulating tumor (ct) DNA RAS mutations in patients with metastatic colorectal cancer (mCRC) treated with panitumumab (pmab) monotherapy from the ASPECCT study

P. Gibbs, Tae Won Kim, T. Price, 2016 .

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.

Ignace Vergote, Beth Y Karlan, Christian Marth, 2016, Gynecologic oncology.

Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study.

B. Monk, B. Karlan, A. Oza, 2015 .

Improved sensitivity and resolution in the flow cytometric DNA analysis of human solid tumor specimens. Use of in vitro fine-needle aspiration and uniform staining reagents.

R. Tubbs, B. Bach, M. Edinger, 1991, American journal of clinical pathology.

Critical elements of quality control and quality assessment in flow cytometric DNA assays

B. Bach, 1992 .

Population-based study of giant cell tumor of bone in Sweden (1983-2011).

A. Liede, P. Sobocki, J. Engellau, 2016, Cancer epidemiology.

A Population Pharmacokinetic Meta‐Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients

H. Xiong, R. Menon, S. Stodtmann, 2021, Journal of clinical pharmacology.

Regional variation and challenges in estimating the incidence of giant cell tumor of bone.

Steven S. Wong, A. Liede, P. Sobocki, 2014, The Journal of bone and joint surgery. American volume.

Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study

H. Groen, T. Owonikoko, J. Fujimoto, 2021, Clinical Cancer Research.

Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone

I. Jacobs, H. Gelderblom, R. Grimer, 2018, World Journal of Surgical Oncology.

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

S. Faivre, L. Licitra, E. Winquist, 2013, The Lancet. Oncology.

Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study.

J. Clarke, J. Patel, M. Dunbar, 2021, Lung cancer.

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma

R. Heist, K. Kelly, E. Vokes, 2021, Clinical Cancer Research.

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

M. Morgan, A. Okamoto, D. Cella, 2019, The New England journal of medicine.

Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.

A. Tafreshi, R. Govindan, Xin Huang, 2022, Clinical lung cancer.

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.

A. Carrato, L. Lipton, C. Fuchs, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial.

H. Wildiers, B. Arun, M. Friedlander, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study

R. Govindan, S. Novello, S. Ramalingam, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.

H. Wildiers, M. Friedlander, B. Arun, 2021, European journal of cancer.

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.

B. Monk, A. Oza, R. Wenham, 2017, European journal of cancer.

Incidence Trends in the Diagnosis of Giant Cell Tumor of Bone in Sweden Since 1958.

A. Liede, H. Bauer, P. Sobocki, 2015, The Journal of bone and joint surgery. American volume.

Safety and Efficacy of Panitumumab (pmab) in HPV Positive (+) and HPV Negative (−) Recurrent/metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): Analysis of the Phase 3 SPECTRUM Trial

E. Winquist, Zhiying Pan, J. Vermorken, 2011 .

Failure of anti-EGFR therapy in p16-positive head and neck cancer - authors' reply.

J. Vermorken, B. Bach, 2013, The Lancet. Oncology.

Multicentre Clinical Trials Evaluating the Breast Biophysical Examination in the Assessment of Breast Disease

B. Bach, 1996 .

Performance status of real-world oncology patients before and after frst course of chemotherapy

J. Kallich, C. Paoli, B. Bach, 2014 .

Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study

J. Douillard, C. Lofton-Day, M. Peeters, 2018, Journal of Cancer Research and Clinical Oncology.

Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer.

Eric F. Johnson, E. Vokes, S. Feigenberg, 2021, Lung Cancer.

PARTNER: A randomized phase II study of docetaxel/cisplatin (doc/cis) chemotherapy with or without panitumumab (pmab) as first-line treatment (tx) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

S. Dakhil, P. Debruyne, L. Wirth, 2013 .

c-Met expression and response to telisotuzumab vedotin (teliso-v) in patients with non-small cell lung cancer.

R. Heist, K. Kelly, D. Camidge, 2019, Journal of Clinical Oncology.